Allianz Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Allianz Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-79,300	Closed	-$1.39M	–	2759
2021 Q3	$1.39M	Buy	+79,300	New	+$926K	﹤0.01%	1795

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Allianz Asset Management's TRIL Position: Q4 2021 in Review

Allianz Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 79,300 shares — an estimated $1.39M sold.

Allianz Asset Management first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $1.39M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Allianz Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Allianz Asset Management sold 79,300 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.39M.
Allianz Asset Management first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Allianz Asset Management's Trillium Therapeutics Inc. position peaked at $1.39M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Allianz Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.